Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GSK3A | P49840 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13190368 | 0.89 | NAMPT (0.45) | TP53LMNAMAPTGSK3ATHRB | |
| SCHEMBL13190371 | 0.85 | ATR (0.40) | MCHR1MAPK14HTR1ADRD2HTR2A | |
| SCHEMBL480706 | 0.85 | ATR (0.40) | MCHR1MAPK14HTR1ADRD2HTR2A | |
| SCHEMBL480705 | 0.85 | ATR (0.40) | MCHR1MAPK14HTR1ADRD2HTR2A | |
| SCHEMBL480804 | 0.85 | ATR (0.40) | MCHR1MAPK14HTR1ADRD2HTR2A | |
| SCHEMBL3436108 | 0.83 | ACHE (0.42) | TP53LMNAMAPTGSK3ATHRB | |
| SCHEMBL13190496 | 0.83 | ACHE (0.42) | TP53LMNAMAPTGSK3ATHRB | |
| SCHEMBL480851 | 0.80 | TP53 (0.40) | TP53LMNAMAPTGSK3ATHRB | |
| SCHEMBL2119989 | 0.78 | MEN1 (0.43) | MCHR1MCHR2 | |
| SCHEMBL2119985 | 0.78 | MEN1 (0.43) | MCHR1MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NNT | TP53 175/4885LMNA 510/4885MAPT 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.